Cetuximab and Other Anti–Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Cetuximab and Other Anti–Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Non-Small Cell Lung Cancer

Published:2009-05-29 Issue:6 Volume:14 Page:601-611
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Gridelli Cesare¹,Maione Paolo¹,Ferrara Marianna Luciana²,Rossi Antonio¹

Affiliation:

1. a Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy

2. b Division of Medical Oncology, Second University of Naples, Naples, Italy

Abstract

Learning Objectives Classify clinical and molecular predictors of outcomes of anti-EGFR monoclonal antibodies. Appraise the clinical results of anti-EGFR monoclonal antibodies in the treatment of patients with NSCLC. Assess the clinical results of therapy with anti-EGFR monoclonal antibodies combined with other new biologic agents in the treatment of patients with NSCLC. This article is available for continuing medical education credit at CME.TheOncologist.com

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2008-0153

Reference69 articles.

1. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003;Pfister;J Clin Oncol,2004

2. Epidermal growth factor-related peptides and their receptors in human malignancies;Salomon;Crit Rev Oncol Haematol,1995

3. Signal transduction by receptors with tyrosine kinase activity;Ullrich;Cell,1990

4. Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment;Normanno;Endocr Relat Cancer,2003

5. Untangling the ErbB signalling network;Yarden;Nat Rev Mol Cell Biol,2001

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study;Journal for ImmunoTherapy of Cancer;2024-03

2. Adoptive T-Cell Therapy for the Treatment of Lung Cancer;Immunotherapy Against Lung Cancer;2024

3. An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC;International Journal of Molecular Sciences;2023-09-13

4. Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer;Cancer Cell International;2021-02-01

5. Understanding the biology and advent of physics of cancer with perspicacity in current treatment therapy;Life Sciences;2019-12